Sharlene Gill, Medical Oncologist and Medical Director of Staff Wellness and Engagement at BC Cancer, shared a post on LinkedIn:
“Back home and reflecting on my top 5 trial takeaways, so here goes:
- KRYSTAL10 – 2L adagrasib + cetux vs CTx in G12Cmut mCRC – higher ORR but no PFS or OS benefit
- EMERALD1 – int HCC TACE + durva + bev improved PFS & ORR vs TACE, but no OS benefit
- ATOMIC adjuvant stage 3 dMMR colon ca – exploratory analysis suggests benefit of atezo limited to >6cy of FOLFOX.
- RMC-9805-001 – zoldonrasib (RAS (ON) G12D) + daraxonrasib (pan-RAS) in 2L+ G12D, ORR 50%, no DLT…phase 3 1L RASolute309 awaited …?chemo-free option
- RMC-GI-102 – zoldonrasib + CT in 1L G12D aPDAC, ORR 82% (mFFX) and 61% (GnP),…phase 3 1L RASolute 305 awaited!
Lots of great education sessions! Special mentions.
ADCs Keynote, Elizabeth Smyth, EAOCRC session, Cathy Eng, RAS inhibition, Zev Wainberg… plus enjoyed catching some beautiful sights in Munich”
Other articles about ESMOGI26 and GI Oncology on OncoDaily.
